Proactive Investors USA & CanadaiBio announces production of biosimilar rituximab drug, shares rallyProactive Investors USA & CanadaiBio (AMEX:IBIO) shares rallied around 10% Wednesday after the company announced that its proprietary iBioLaunch technol…
iBio Announces Production of Biosimilar Rituximab with its iBioLaunch™ TechnologySacramento BeeRituximab is a chimeric mouse-human monoclonal antibody that binds to the CD20 antigen presented on the B-cell surface. Scientists at iBio's research a…
InPharmMerck KGaA signs MS and cancer research dealInPharmIn August Biogen and Abbott's MS drug daclizumab, a new injectable, performed well in a Phase IIb study, although two deaths marred the overall results. But Novartis' oral drug Gilenya (…
Biogen Idec (BIIB) Upgraded by William Blair to "Outperform"LocalizedUSAIt includes BG-12, Daclizumab, Fampridine, GA101, Humanized Anti-CD20 MAb (ocrelizumab), Lixiavaptan, Long-Acting rFactor IX and PEGylated interferon beta-1a. Shares of B…
Norfolk Eastern Daily PressUK's NICE Rebuffs Glaxo's New Lupus Drug BenlystaWall Street JournalNICE also said Benlysta should be compared with rituximab, sold by Roche Holding AG (ROG.VX), because some people with severe lupus currently receive…
Long-term data on rituximab in DLBCLOncology UpdateRituximab's efficacy with CHOP in diffuse large-B-cell lymphoma at six years has been demonstrated in a study published in the Lancet this week. The follow-up of the MInT trial was “reassuring”…
The Daily DealAbbott's emerging entranceThe Daily DealFacet had partnered with Biogen Idec Inc. on a multiple sclerosis drug, known as daclizumab, a monoclonal antibody being considered for uses ranging from the prevention of organ rejection in tra…
Abbott Laboratories Offering Investors Expanded Late-Stage Drug PipelineSeeking AlphaWith the purchase came multiple-sclerosis drug daclizumab and late-stage multiple-myeloma treatment elotuzumab, which have both given encouraging Phase II data so far….